Royal Marsden trial leads to practice changing milestone for advanced anal cancer

June 12, 2020

Results from the first ever randomised clinical trial in advanced anal cancer patients, led and supported by The Royal Marsden NHS Foundation Trust and Cancer Research UK, in collaboration with colleagues in the US, Norway and Australia, has led to a practice changing milestone with a new approach to treatment which is safer and more effective than previously recommended treatments for this group of patients.

Published in the Journal of Clinical Oncology today, (Friday 12th June 2020), researchers found that a chemotherapy combination of carboplatin and paclitaxel - which is primarily used to treat other cancers, including ovarian, womb and lung cancer - performed better overall with anal cancer patients living seven months longer compared to chemotherapy treatment with cisplatin and 5-fluorouracil. These results have led to a direct change in recommended treatment guidelines in both European and American clinical practice (The European Society for Medical Oncology and National Comprehensive Cancer Network clinical practice guidelines).

Around 1,300 people are diagnosed with anal cancer each year in the UK and this number is rising by around three per cent per year. Due to small patient populations, there has previously been very limited evidence to guide treatment decisions. The findings from this study have set a new standard of care for this rare type of cancer, gaining international consensus among clinicians for the first time.

The international randomised phase II trial, led by The Royal Marsden NHS Foundation Trust, analysed data from 91 patients in four countries, including the UK, Norway, the US and Australia. This study was supported by the International Rare Cancers Initiative (IRCI) a global collaboration aimed at improving outcomes for patients with rare cancers. This is the first IRCI trial of its kind to complete and report its results.

This study was funded by The Royal Marsden's GI and Lymphoma Unit, the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research, London (ICR), Cancer Research UK and The Royal Marsden Cancer Charity.

Study Chief-Investigator Dr Sheela Rao, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

"The results of this study have led to an immediate change in patient care. While treatment with cisplatin and 5-fluorouracil was generally considered a reasonable option for advanced anal cancer, we now know that carboplatin and paclitaxel is more effective and better tolerated. In our study, these patients lived seven months longer overall and experienced less treatment side effects.

"This is a great example of international collaboration for a rare cancer with the results having a direct impact on recommended guidelines which will benefit patients with anal cancer from around the world.

"Around 30 per cent of people with anal cancer will develop advanced disease which cannot be treated surgically, and all of these patients are eligible to receive this chemotherapy combination."

Deborah Pink, 58, was a patient on this trial who has benefitted from receiving the newly recommended chemotherapy combination. Deborah has been receiving treatment at The Royal Marsden since she was diagnosed with anal cancer in 2011. She said:

"After my diagnosis things moved very quickly and I've had a number of different treatments, surgery and radiotherapy. When I first started this trial a few years ago, I had a complete response to the chemotherapy combination of carboplatin and paclitaxel and doctors at the Royal Marsden saw a reduction in the size of my tumour which was such positive news to hear. Being on the trial was a great opportunity and knowing the results are benefitting other patients like myself makes a real difference, it's really encouraging to know that research is being done in this area for such a rare type of cancer. Currently, I am continuing with this type of chemotherapy treatment and am monitored under the hospital with regular scans. Without this treatment and the ongoing care I've had at The Royal Marsden over the last nine years, I might not have been here."

Martin Ledwick, Cancer Research UK's head information nurse, said:

"These results clearly demonstrate the need for ongoing research so that we can continually improve treatments for people with cancer. Without support for well-designed clinical trials, important improvements in treatment like this can't be identified."
-end-
For more information please contact Francesca Vitale, Senior Press and PR Officer at The Royal Marsden on Francesca.vitale@rmh.nhs.uk or 07584 441 432.

About The Royal Marsden NHS Foundation Trust

The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.

Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe seeing and treating over 59,000 NHS and private patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.

The Royal Marsden, with the ICR, is the only National Institute for Health Research Biomedical Research Centre for Cancer. This supports pioneering research work carried out over a number of different cancer themes.

The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden, a world-leading cancer centre. It ensures Royal Marsden nurses, doctors and research teams can provide the very best care and develop life-saving treatments, which are used across the UK and around the world.

From funding state-of-the-art equipment and ground-breaking research, to creating the very best patient environments, The Royal Marsden Cancer Charity will never stop looking for ways to improve the lives of people affected by cancer.

The Royal Marsden NHS Foundation Trust

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.